RU2487712C2 - Никотиновые иммунонанотерапевтические лекарственные средства - Google Patents
Никотиновые иммунонанотерапевтические лекарственные средства Download PDFInfo
- Publication number
- RU2487712C2 RU2487712C2 RU2011118880/15A RU2011118880A RU2487712C2 RU 2487712 C2 RU2487712 C2 RU 2487712C2 RU 2011118880/15 A RU2011118880/15 A RU 2011118880/15A RU 2011118880 A RU2011118880 A RU 2011118880A RU 2487712 C2 RU2487712 C2 RU 2487712C2
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- nicotine
- cells
- nanocarriers
- binding
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000002539 nanocarrier Substances 0.000 claims abstract 21
- 239000000203 mixture Substances 0.000 claims abstract 18
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical group CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract 12
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract 11
- 229960002715 nicotine Drugs 0.000 claims abstract 11
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract 10
- 230000028993 immune response Effects 0.000 claims abstract 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 3
- 239000002671 adjuvant Substances 0.000 claims abstract 3
- 230000002163 immunogen Effects 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 229920000642 polymer Polymers 0.000 claims 7
- 239000000758 substrate Substances 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 229920001600 hydrophobic polymer Polymers 0.000 claims 3
- 210000002540 macrophage Anatomy 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 238000000159 protein binding assay Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 229930182840 (S)-nicotine Natural products 0.000 claims 1
- 229940123189 CD40 agonist Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 230000028996 humoral immune response Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000008348 humoral response Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Предложена композиция для никотиновой иммунонанотерапии, содержащая синтетические наноносители, имеющие полимерную поверхность, конъюгированную со множеством никотиновых остатков, причем множество никотиновых остатков на наноносителе образуют иммуногенную поверхность, обеспечивающую низкую аффинность, высокоавидное связывание никотиновых остатков к поверхностям антигенпрезентирующей клетки (АПК) по сравнению со связыванием антитела, и фармацевтически приемлемый эксципиент. Изобретение обеспечивает наноносители, способные стимулировать иммунный ответ в Т-клетках и/или В-клетках и продуцирование антиникотин-антител, причем гуморальный и клеточный ответ может достигаться в отсутствии экзогенного адъюванта. Это обеспечивает отсутствие неспецифического ответа на воспаление, вызванного адъювантом. 16 з.п. ф-лы, 37 ил.
Description
Claims (17)
1. Композиция для никотиновой иммунонанотерапии, содержащая:
(1) синтетические наноносители, имеющие полимерную поверхность, конъюгированную со множеством никотиновых остатков, имеющих приведенную ниже структуру, или его метаболит,
причем никотин ковалентно связан с полимером или липидом посредством одного из R1-R7, представляющих Н, где R8 представляет собой алкильную группу; и
причем множество никотиновых остатков на наноносителе образуют иммуногенную поверхность, обеспечивающую низкую аффинность, высокоавидное связывание никотиновых остатков к поверхностям антигенпрезентирующей клетки (АПК) по сравнению со связыванием антитела;
причем наноносители необязательно содержат один или более нацеливающих агентов, распознающих мишень, ассоциированную с конкретными органом, тканью, клеткой или субклеточным местом действия, и необязательно содержат один или более иммуномодулирующих агентов, индуцирующих иммунный ответ в В-клетках или Т-клетках или стимулирующих иммунную систему таким образом, что иммунный ответ усиливается, подавляется направляется или перенаправляется; и
(2) фармацевтически приемлемый эксципиент.
(1) синтетические наноносители, имеющие полимерную поверхность, конъюгированную со множеством никотиновых остатков, имеющих приведенную ниже структуру, или его метаболит,
причем никотин ковалентно связан с полимером или липидом посредством одного из R1-R7, представляющих Н, где R8 представляет собой алкильную группу; и
причем множество никотиновых остатков на наноносителе образуют иммуногенную поверхность, обеспечивающую низкую аффинность, высокоавидное связывание никотиновых остатков к поверхностям антигенпрезентирующей клетки (АПК) по сравнению со связыванием антитела;
причем наноносители необязательно содержат один или более нацеливающих агентов, распознающих мишень, ассоциированную с конкретными органом, тканью, клеткой или субклеточным местом действия, и необязательно содержат один или более иммуномодулирующих агентов, индуцирующих иммунный ответ в В-клетках или Т-клетках или стимулирующих иммунную систему таким образом, что иммунный ответ усиливается, подавляется направляется или перенаправляется; и
(2) фармацевтически приемлемый эксципиент.
2. Композиция по п.1, в которой наноносители содержат один или более нацеливающих агентов, узнающих мишень, ассоциированную с конкретными органом, тканью, клеткой или субклеточным местом действия, или один или более иммуномодулирующих агентов, индуцирующих иммунный ответ в В-клетках или Т-клетках или стимулирующих иммунную систему таким образом, что иммунный ответ усиливается, подавляется, направляется или перенаправляется, причем нацеливающие агенты или иммуностимулирующие агенты ассоциированы с поверхностью наноносителей или инкапсулированы в наноносители.
3. Композиция по п.1, где синтетические наноносители способны активировать антиген презентирующих клеток, В-клеток, CD4+ Т-клеток, NKT-клеток или любая комбинация этих типов клеток при введении человеку.
4. Композиция по п.1, где синтетические наноносители способны стимулировать продуцирование анти-никотин-IgG-антител при введении человеку.
5. Композиция по п.1, где синтетические наноносители способны индуцировать гуморальный иммунный ответ у пациента-человека.
6. Композиция по п.1, где синтетические наноносители вводят пациенту-человеку, причем эти синтетические наноносители способны переноситься через стенку субкапсулярного синуса (SCS) макрофагами SCS в организме пациента.
7. Композиция по п.2, где иммуностимулирующий агент выбран из группы, состоящей из агониста TLR, интерлейкина, интерферона, цитокина, CD40 агониста, агониста инфламмасомы и адъюванта.
8. Композиция по п.1, где синтетические наноносители содержат полимерные молекулы и где множество никотиновых остатков ковалентно присоединены к этим полимерным молекулам.
9. Композиция по п.8, где множество никотиновых остатков являются (S)-(-)-никотиновыми остатками и где синтетические наноносители содержат полимер, имеющий структуру (X)n-L1-(Y)m-L2-A, где: Х обозначает сегмент гидрофобного полимера; Y обозначает сегмент гидрофильного полимера; n и m выбраны из 0 и 1, при условии, что n и m не являются оба 0; L1 и L2 независимо выбраны из связи и линкерной группы; и А обозначает (S)-(-)-никотин.
10. Композиция по п.1, где R8 представляет собой метил.
11. Композиция по п.1, где никотин присутствует на поверхности наноносителей в плотности, равной или большей, чем плотность, необходимая для получения по меньшей мере 10% максимальной иммобилизации, наблюдаемой для моноклонального антитела (МАb) в анализе связывания антигенпрезентирующих клеток (АРС), при условии, что в анализе связывания АРС плотность полумаксимального связывания для множества остатков является по меньшей мере в два раза большей, чем плотность полумаксимального связывания для этого МАb.
12. Композиция по п.11, где никотин присутствует на поверхности наноносителей в плотности, равной или большей, чем плотность, необходимая для получения по меньшей мере 20% максимальной иммобилизации, наблюдаемой для МАb в анализе связывания АРС.
13. Композиция по п.11, где МАb является клоном AD5-8E7 анти-CD1c (BDCA-1) или клоном 3D6.112, изотипом IgG2a крысиного анти-СD169 мыши-антитела, и плотность полумаксимального связывания для никотина является по меньшей мере в четыре раза большей, чем плотность полумаксимального связывания для МАb.
14. Композиция по п.11, где анализ связывания АРС включает:
(а) получение множества субстратов, имеющих покрытия из функционального остатка при множестве плотностей покрытия поверхности, где указанный функциональный остаток способен связываться с дендритной клеткой (DC) или рецепторами поверхности макрофагов субкапсулярного синуса;
(b) приведение в контакт множества субстратов с суспензиями отдельных клеток DC или макрофагов субкапсулярного синуса в течение заранее определенного периода времени;
(c) удаление несвязавшихся АРС из множества субстратов и фиксирование связанных АРС с множеством субстратов;
(d) определение количества связанных АРС на единицу площади поверхности для каждого субстрата в множестве субстратов;
(e) построение графика зависимости результата из (d) от плотности покрытия функционального остатка;
(f) получение величины максимальной иммобилизации определением максимального количества связанных АРС на единицу площади поверхности множества субстратов; и
(g) получение величины плотности полумаксимального связывания определением плотности покрытия поверхности, которая обеспечивает 50% максимума.
(а) получение множества субстратов, имеющих покрытия из функционального остатка при множестве плотностей покрытия поверхности, где указанный функциональный остаток способен связываться с дендритной клеткой (DC) или рецепторами поверхности макрофагов субкапсулярного синуса;
(b) приведение в контакт множества субстратов с суспензиями отдельных клеток DC или макрофагов субкапсулярного синуса в течение заранее определенного периода времени;
(c) удаление несвязавшихся АРС из множества субстратов и фиксирование связанных АРС с множеством субстратов;
(d) определение количества связанных АРС на единицу площади поверхности для каждого субстрата в множестве субстратов;
(e) построение графика зависимости результата из (d) от плотности покрытия функционального остатка;
(f) получение величины максимальной иммобилизации определением максимального количества связанных АРС на единицу площади поверхности множества субстратов; и
(g) получение величины плотности полумаксимального связывания определением плотности покрытия поверхности, которая обеспечивает 50% максимума.
15. Композиция по п.1, в которой наноноситель представляет собой самособирающийся синтетический наноноситель, образованный из амфифильных молекул, содержащий гидрофильные иммуномодулирующие или антигенные молекулы, ковалентно связанные с гидрофобным полимером.
16. Композиция по п.9, где гидрофильный полимер представляет собой полиэтиленгликоль, а гидрофобный полимер представляет собой полигликолевую кислоту, полимолочную кислоту или поли(молочную кислоту/гликолевую кислоту).
17. Композиция по п.1, где наноносители содержат полимер, причем никотин связан с полимером.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USPCT/US2008/011932 | 2008-10-12 | ||
PCT/US2008/011932 WO2009051837A2 (en) | 2007-10-12 | 2008-10-12 | Vaccine nanotechnology |
US12/428,388 US8591905B2 (en) | 2008-10-12 | 2009-04-22 | Nicotine immunonanotherapeutics |
US12/428,388 | 2009-04-22 | ||
PCT/US2009/060236 WO2010042866A1 (en) | 2008-10-12 | 2009-10-09 | Nicotine immunonanotherapeutics |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011118880A RU2011118880A (ru) | 2012-11-20 |
RU2487712C2 true RU2487712C2 (ru) | 2013-07-20 |
Family
ID=42099036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011118880/15A RU2487712C2 (ru) | 2008-10-12 | 2009-10-09 | Никотиновые иммунонанотерапевтические лекарственные средства |
Country Status (12)
Country | Link |
---|---|
US (2) | US8591905B2 (ru) |
EP (1) | EP2346528B1 (ru) |
JP (1) | JP5854837B2 (ru) |
KR (1) | KR20110074903A (ru) |
CN (1) | CN102245200A (ru) |
AU (1) | AU2009303334B2 (ru) |
BR (1) | BRPI0920282A2 (ru) |
CA (1) | CA2740248C (ru) |
IL (1) | IL212244A (ru) |
MX (1) | MX336721B (ru) |
RU (1) | RU2487712C2 (ru) |
WO (1) | WO2010042866A1 (ru) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US9267937B2 (en) * | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9217129B2 (en) * | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
WO2008124632A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
AU2008314647B2 (en) | 2007-10-12 | 2013-03-21 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8277812B2 (en) * | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
MY160201A (en) * | 2008-12-09 | 2017-02-28 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
JP6297776B2 (ja) * | 2009-05-27 | 2018-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. | 免疫調節薬−高分子化合物 |
US10327467B2 (en) | 2010-04-14 | 2019-06-25 | Altria Client Services Llc | Preformed smokeless tobacco product |
EP2575876B1 (en) * | 2010-05-26 | 2017-12-06 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
JP6017422B2 (ja) | 2010-08-10 | 2016-11-02 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 赤血球結合療法 |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
JP2013540162A (ja) * | 2010-10-22 | 2013-10-31 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 抗原特異的な寛容を誘導する微粒子およびその使用 |
WO2012061717A1 (en) * | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
KR102112002B1 (ko) | 2011-04-29 | 2020-05-18 | 셀렉타 바이오사이언시즈, 인크. | 치료적 단백질에 대해 면역 반응을 감소시키는 관용원성 합성 나노운반체 |
MX2014001142A (es) * | 2011-07-29 | 2014-02-27 | Selecta Biosciences Inc | Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl). |
JP2014532799A (ja) * | 2011-11-09 | 2014-12-08 | アセンド・バイオファーマシューティカルズ・リミテッド | 免疫調節結合体 |
WO2013082503A1 (en) * | 2011-12-01 | 2013-06-06 | Flow Pharma, Inc. | Peptide particle formulation |
EP2606897A1 (en) * | 2011-12-22 | 2013-06-26 | Laboratorios Del. Dr. Esteve, S.A. | Methods and compositions for the treatment of diseases caused by enveloped viruses |
KR101778169B1 (ko) * | 2012-04-11 | 2017-09-13 | 리폭센 테크놀로지즈 리미티드 | 미엘린염기성단백질의 올리고펩티드 단편을 함유하는 리포솜, 의약조성물 및 다발성경화증의 치료법 |
KR102247979B1 (ko) * | 2012-05-25 | 2021-05-04 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 t 세포의 조작 방법 |
US10799548B2 (en) | 2013-03-15 | 2020-10-13 | Altria Client Services Llc | Modifying taste and sensory irritation of smokeless tobacco and non-tobacco products |
CN105339012A (zh) | 2013-05-03 | 2016-02-17 | 西莱克塔生物科技公司 | 降低i型和iv型超敏反应的致耐受性合成纳米载体的局部伴随施用 |
US20140357723A1 (en) * | 2013-05-29 | 2014-12-04 | Uwe-Bernd Bernd Ross | Tricholine Nasal Formulation and Method of Use |
AU2015233084B2 (en) | 2014-02-21 | 2020-12-17 | Anokion Sa | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
CA2957800A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
US9622973B1 (en) * | 2016-03-08 | 2017-04-18 | King Saud University | Poly ε-caprolactone-ethoxylated fatty acid copolymers |
US11484507B2 (en) | 2016-11-02 | 2022-11-01 | Hillstream Biopharma, Inc. | Polymeric nanoparticles providing nucleic acids encoding TNF-α |
WO2018128610A1 (en) * | 2017-01-05 | 2018-07-12 | Chenming Zhang | Nicotine nanovaccines and uses thereof |
WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
EP3700549A4 (en) | 2017-10-27 | 2021-08-18 | Children's Medical Center Corporation | LIPIDS BASED ON SHORT CHAIN CERAMIDES AND THEIR USES |
EP3773564A4 (en) * | 2018-04-12 | 2022-04-20 | Children's Medical Center Corporation | CERAMIDE LIPID-BASED DELIVERY VEHICLES AND THEIR USES |
US20220193108A1 (en) * | 2019-04-10 | 2022-06-23 | Wake Forest University Health Sciences | Immunotherapeutic Nanoparticles And Methods Relating Thereto |
CN112569237B (zh) * | 2019-09-30 | 2022-12-02 | 武汉大学 | 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用 |
CN112773894A (zh) * | 2019-11-07 | 2021-05-11 | 华南师范大学 | 一种基于多功能的黑磷纳米粒子的光声免疫治疗的纳米复合体及其制备方法 |
AU2020407871A1 (en) | 2019-12-20 | 2022-06-30 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof |
CN113115873A (zh) * | 2019-12-30 | 2021-07-16 | 黑龙江北货郎森林食品有限公司 | 一种含黑木耳活性肽的清肺饮品及其制备方法 |
WO2021231904A1 (en) * | 2020-05-14 | 2021-11-18 | Diomics Corporation | Detection and indication of covid-19, other viruses and pathogens and vaccine associated efficacy |
US20240124396A1 (en) * | 2021-02-07 | 2024-04-18 | Shenzhen Shenxin Biotechnology Co., Ltd. | Amino lipid compound, preparation method therefor, and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5942252A (en) * | 1986-10-24 | 1999-08-24 | Southern Research Institute | Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their release |
US6232082B1 (en) * | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
CA2453959A1 (en) * | 2001-07-17 | 2003-01-30 | Universidade Federal De Minas Gerais-Ufmg | Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres |
US20040059094A1 (en) * | 2002-07-18 | 2004-03-25 | Bachmann Martin F. | Hapten-carrier conjugates and uses thereof |
WO2005112885A2 (en) * | 2004-05-12 | 2005-12-01 | Baxter International Inc. | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
CA2649149A1 (en) * | 2006-04-11 | 2007-10-25 | Koko Kosmetikvertrieb Gmbh & Co. Kg | Nanoparticle containing nicotine and/or cotinine, dispersions, and use thereof |
Family Cites Families (371)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3766774A (en) | 1972-02-18 | 1973-10-23 | H Clark | Apparatus and method for measuring blood characteristics |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
US4446122A (en) | 1979-12-28 | 1984-05-01 | Research Corporation | Purified human prostate antigen |
USRE33405E (en) | 1979-12-28 | 1990-10-23 | Research Corporation Technologies, Inc. | Purified human prostate antigen |
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US4795436A (en) | 1983-11-14 | 1989-01-03 | Bio-Mimetics, Inc. | Bioadhesive composition and method of treatment therewith |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
GB8601100D0 (en) | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
US4970299A (en) | 1986-07-03 | 1990-11-13 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies selective for prostate cancer |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
US5759830A (en) | 1986-11-20 | 1998-06-02 | Massachusetts Institute Of Technology | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
FR2608988B1 (fr) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US4903649A (en) | 1987-03-12 | 1990-02-27 | Brunswick Corporation | Fuel supply system with pneumatic amplifier |
US4902615A (en) | 1987-03-27 | 1990-02-20 | Biosciences Corporation Of Texas | Detection of human cancer cells with antibodies to human cancer nucleolar antigen p120 |
DE3812289C2 (de) | 1987-04-20 | 1995-06-08 | Mitsubishi Electric Corp | Leerlaufdrehzahlregelvorrichtung für eine Brennkraftmaschine |
US4839416A (en) | 1987-06-09 | 1989-06-13 | Ampad Corporation | Low tack microsphere adhesive |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5069936A (en) | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
US5200181A (en) | 1988-01-11 | 1993-04-06 | Massachusetts Institute Of Technology | Oral bilirubin therapy |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
JPH0249596A (ja) | 1988-08-09 | 1990-02-19 | Masamichi Ueda | ヒト前立腺上皮細胞の表面に特異的に反応するモノクローナル抗体 |
US4959219A (en) | 1988-08-15 | 1990-09-25 | Fisons Corporation | Coating barriers comprising ethyl cellulose |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
EP0398903B1 (en) | 1988-12-09 | 1992-06-17 | Robert Bosch Gmbh | Method for acceleration enrichment in fuel injection systems |
US5334497A (en) | 1988-12-13 | 1994-08-02 | Hideki Inaba | Method of feeding a substrate into tubular bioreactor |
US4976968A (en) | 1989-02-24 | 1990-12-11 | Clinical Technologies Associates, Inc. | Anhydrous delivery systems for pharmacological agents |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
EP0499619B1 (en) | 1989-11-06 | 1996-02-07 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5240963A (en) | 1990-01-19 | 1993-08-31 | Nova Pharmaceutical Corporation | Branched polyanhydrides |
US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US6001577A (en) | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5853984A (en) | 1990-06-11 | 1998-12-29 | Nexstar Pharmaceuticals, Inc. | Use of nucleic acid ligands in flow cytometry |
US5874218A (en) | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
US6716580B2 (en) | 1990-06-11 | 2004-04-06 | Somalogic, Inc. | Method for the automated generation of nucleic acid ligands |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US6280932B1 (en) | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
US5789163A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Enzyme linked oligonucleotide assays (ELONAS) |
KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US6699474B1 (en) | 1990-08-20 | 2004-03-02 | Erich Hugo Cerny | Vaccine and immunserum against drugs of abuse |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5175296A (en) | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
US5403750A (en) | 1991-03-06 | 1995-04-04 | W. R. Grace & Co.-Conn. | Biocompatible, low protein adsorption affinity matrix |
IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5470944A (en) * | 1992-02-13 | 1995-11-28 | Arch Development Corporation | Production of high molecular weight polylactic acid |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US6197346B1 (en) | 1992-04-24 | 2001-03-06 | Brown Universtiy Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
US6608201B2 (en) | 1992-08-28 | 2003-08-19 | 3M Innovative Properties Company | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5928647A (en) | 1993-01-11 | 1999-07-27 | Dana-Farber Cancer Institute | Inducing cytotoxic T lymphocyte responses |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5820879A (en) | 1993-02-12 | 1998-10-13 | Access Pharmaceuticals, Inc. | Method of delivering a lipid-coated condensed-phase microparticle composition |
US5916539A (en) | 1993-03-02 | 1999-06-29 | Silica Gel Ges. M.B.H. | Superparamagnetic particles, process for producing the same and their use |
US5342781A (en) | 1993-07-15 | 1994-08-30 | Su Wei Wen W | External-loop perfusion air-lift bioreactor |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
GB9412273D0 (en) * | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5786204A (en) | 1995-01-20 | 1998-07-28 | Human Genome Sciences, Inc. | Human prostatic specific reductase |
US5686113A (en) | 1995-03-21 | 1997-11-11 | Temple University Of The Commonwealth System Of Higher Education | Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses |
US5876727A (en) | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
US6902743B1 (en) | 1995-05-22 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US20020150578A1 (en) | 1995-06-05 | 2002-10-17 | Human Genome Sciences, Inc. | Human prostatic specific reductase |
US5843732A (en) | 1995-06-06 | 1998-12-01 | Nexstar Pharmaceuticals, Inc. | Method and apparatus for determining consensus secondary structures for nucleic acid sequences |
US5879712A (en) | 1995-06-07 | 1999-03-09 | Sri International | Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
WO1997004747A1 (en) | 1995-07-27 | 1997-02-13 | Dunn James M | Drug delivery systems for macromolecular drugs |
US6096344A (en) | 1995-07-28 | 2000-08-01 | Advanced Polymer Systems, Inc. | Bioerodible porous compositions |
US6395770B1 (en) | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
FR2742357B1 (fr) | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | Nanoparticules stabilisees et filtrables dans des conditions steriles |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20020106647A1 (en) | 1996-07-24 | 2002-08-08 | Segal Andrew H. | Nucleic acid compositions and methods of introducing nucleic acids into cells |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US6767702B2 (en) | 1996-07-29 | 2004-07-27 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
WO1998008856A2 (de) | 1996-08-30 | 1998-03-05 | Fuerste Jens Peter | Spiegelselektion und spiegelevolution von nucleinsäuren |
WO1998009523A1 (en) | 1996-09-05 | 1998-03-12 | Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
US6368598B1 (en) | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
US6120666A (en) | 1996-09-26 | 2000-09-19 | Ut-Battelle, Llc | Microfabricated device and method for multiplexed electrokinetic focusing of fluid streams and a transport cytometry method using same |
ES2290969T3 (es) | 1996-10-25 | 2008-02-16 | Minnesota Mining And Manufacturing Company | Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas. |
US7518013B2 (en) | 2000-08-24 | 2009-04-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators |
US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US6995284B2 (en) | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US7205437B2 (en) | 1996-11-27 | 2007-04-17 | University Of Tennessee Research Foundation | Selective androgen receptor modulators |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
CA2290756A1 (en) | 1997-05-15 | 1998-11-19 | Cytogen Corporation | Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
GB9713980D0 (en) | 1997-07-03 | 1997-09-10 | Danbiosyst Uk | New conjugates |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
US6190913B1 (en) * | 1997-08-12 | 2001-02-20 | Vijay Singh | Method for culturing cells using wave-induced agitation |
US7001996B1 (en) | 1997-08-21 | 2006-02-21 | The United States Of America As Represented By The Secretary Of The Army | Enzymatic template polymerization |
US6451527B1 (en) | 1997-08-29 | 2002-09-17 | Selective Genetics, Inc. | Methods using genetic package display for selecting internalizing ligands for gene delivery |
US20040136961A1 (en) | 1997-10-09 | 2004-07-15 | Ales Prokop | Nanoparticulate composition for efficient gene transfer |
DE19745950A1 (de) | 1997-10-17 | 1999-04-22 | Dds Drug Delivery Service Ges | Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation |
AU734476B2 (en) | 1997-11-05 | 2001-06-14 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
US6254890B1 (en) | 1997-12-12 | 2001-07-03 | Massachusetts Institute Of Technology | Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids |
US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
SE9801923D0 (sv) | 1998-05-29 | 1998-05-29 | Independent Pharmaceutical Ab | Nicotine vaccine |
DE19827164A1 (de) | 1998-06-18 | 1999-12-23 | Merck Patent Gmbh | Katalytisch Titan(IV)-oxid vermittelte geminale symmetrische Dialkylierung von Carbonsäureamiden |
US6265608B1 (en) | 1998-06-30 | 2001-07-24 | Eastman Chemical Company | Method of purifying aromatic dicarboxylic acids |
US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
US6429200B1 (en) | 1998-07-17 | 2002-08-06 | Mirus Corporation | Reverse micelles for delivery of nucleic acids |
DE19839214C1 (de) | 1998-08-28 | 2000-05-25 | Aventis Res & Tech Gmbh & Co | Verfahren zur Herstellung von sphärischen Mikropartikeln mit glatter Oberfläche, die ganz oder teilweise aus mindestens einem wasserunlöslichen linearen Polysaccharid bestehen, sowie mit diesem Verfahren erhältliche Mikropartikel und deren Verwendung |
EA003634B1 (ru) | 1998-10-05 | 2003-08-28 | Фармэкса А/С | Новые способы терапевтической вакцинации |
WO2000021572A2 (en) | 1998-10-09 | 2000-04-20 | The University Of Michigan | Hydrogels and water soluble polymeric carriers for drug delivery |
US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
CZ20012446A3 (cs) | 1999-01-08 | 2002-01-16 | 3M Innovative Properties Company | Farmaceutický prostředek pro léčbu onemocnění sliznice |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20030054360A1 (en) | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
JP2002536640A (ja) | 1999-02-03 | 2002-10-29 | アクララ バイオサイエンシーズ, インコーポレイテッド | 微小流体導入の際のマルチチャネル制御 |
US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
GB9905136D0 (en) | 1999-03-06 | 1999-04-28 | Danbiosyst Uk | Surface modification of lamellar particles |
US6943235B1 (en) | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
US6528499B1 (en) | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
US20020102613A1 (en) | 1999-05-18 | 2002-08-01 | Hoogenboom Hendricus Renerus Jacobus Mattheus | Novel Fab fragment libraries and methods for their use |
AU780474B2 (en) | 1999-06-16 | 2005-03-24 | Boston Biomedical Research Institute Incorporated | Immunological control of beta-amyloid levels in vivo |
US6506887B1 (en) | 1999-07-29 | 2003-01-14 | Somalogic, Incorporated | Conditional-selex |
DE60041333D1 (de) | 1999-08-12 | 2009-02-26 | Agensys Inc | Hen prostatkrebs exprimiert wird, und deren verwendungen |
US20020009466A1 (en) | 1999-08-31 | 2002-01-24 | David J. Brayden | Oral vaccine compositions |
US7429639B2 (en) | 1999-09-29 | 2008-09-30 | Ludwig Institute For Cancer Research | SSX-2 peptides presented by HLA class II molecules |
AU6132700A (en) | 1999-09-30 | 2001-04-05 | Chienna B.V. | Polymers loaded with bioactive agents |
US6790631B1 (en) | 1999-10-05 | 2004-09-14 | Agensys, Inc. | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
WO2001047501A1 (en) | 1999-12-29 | 2001-07-05 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
US7534417B2 (en) | 2000-02-24 | 2009-05-19 | Agensys, Inc. | 103P2D6: tissue specific protein highly expressed in various cancers |
SE0000933D0 (sv) | 2000-03-21 | 2000-03-21 | Independent Pharmaceutica Ab | Method of producing 6-substituted (S)-nicotine derivatives and intermediate compounds |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
US7217770B2 (en) | 2000-05-17 | 2007-05-15 | Samyang Corporation | Stable polymeric micelle-type drug composition and method for the preparation thereof |
US6610713B2 (en) | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US20020151004A1 (en) | 2000-07-24 | 2002-10-17 | Roger Craig | Delivery vehicles and methods for using the same |
US20030232792A1 (en) | 2000-08-24 | 2003-12-18 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
US6998500B2 (en) | 2000-08-24 | 2006-02-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7026500B2 (en) | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
PT1401801E (pt) | 2000-08-24 | 2007-02-28 | Univ Tennessee Res Foundation | Modulares selectivos de receptor de androgénio e métodos para a sua utilização |
IL154425A0 (en) | 2000-08-24 | 2003-09-17 | Univ Tennessee Res H Corp | Selective androgen receptor modulators and methods of use thereof |
US6838484B2 (en) | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
US20020173495A1 (en) | 2000-08-24 | 2002-11-21 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
US20040260108A1 (en) | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
US6503538B1 (en) | 2000-08-30 | 2003-01-07 | Cornell Research Foundation, Inc. | Elastomeric functional biodegradable copolyester amides and copolyester urethanes |
US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
US20040067196A1 (en) * | 2000-10-11 | 2004-04-08 | Brunke Karen J. | Targeted therapeutic lipid constructs |
US6589562B1 (en) | 2000-10-25 | 2003-07-08 | Salvona L.L.C. | Multicomponent biodegradable bioadhesive controlled release system for oral care products |
HU230458B1 (hu) | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Az RNS interferenciát közvetítő kis RNS molekulák |
US6623761B2 (en) | 2000-12-22 | 2003-09-23 | Hassan Emadeldin M. | Method of making nanoparticles of substantially water insoluble materials |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
DE60214134T2 (de) | 2001-02-07 | 2007-07-19 | Beth Israel Deaconess Medical Center, Boston | Modifizierte psma-liganden und deren verwendung |
US7097837B2 (en) | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
US7326564B2 (en) | 2001-02-20 | 2008-02-05 | St. Jude Medical, Inc. | Flow system for medical device evaluation and production |
DE50105026D1 (de) | 2001-03-22 | 2005-02-10 | Cognis Iberia Sl | Nanokapseln |
WO2002076469A1 (en) | 2001-03-27 | 2002-10-03 | Baylor College Of Medicine | A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity |
US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
EP2545937A1 (en) | 2001-06-05 | 2013-01-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
DE60140863D1 (de) | 2001-06-10 | 2010-02-04 | Noxxon Pharma Ag | Verwendung von L-Polynukleotiden zur diagnostischen Bilderzeugung |
US20030022868A1 (en) | 2001-06-25 | 2003-01-30 | Dalton James T. | Selective androgen receptor modulators and methods of use thereof |
AU2775402A (en) | 2001-06-29 | 2003-01-02 | Medimolecular Pty Ltd | Nucleic acid ligands to complex targets |
JP4088251B2 (ja) | 2001-07-02 | 2008-05-21 | オリエンタル酵母工業株式会社 | ニコチンアミドアデニンジヌクレオチドリン酸(nadp)の製造方法 |
EP1279404A1 (en) | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
AU2002326561B2 (en) | 2001-08-07 | 2008-04-03 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
AU2002355910B2 (en) | 2001-08-16 | 2006-07-27 | Calysta As | Method of fermentation |
US20060004042A1 (en) | 2001-08-23 | 2006-01-05 | Dalton James T | Formulations comprising selective androgen receptor modulators |
US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
CN1599623B (zh) | 2001-09-14 | 2011-05-11 | 赛托斯生物技术公司 | 免疫刺激物向病毒样颗粒内的包装:制备方法与用途 |
WO2003028657A2 (en) | 2001-10-03 | 2003-04-10 | The Johns Hopkins University | Compositions for oral gene therapy and methods of using same |
US20030134810A1 (en) | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
ES2541908T3 (es) | 2001-10-10 | 2015-07-28 | Pierre Fabre Medicament | Microesferas biodegradables de liberación prolongada y su procedimiento de preparación |
CA2463172C (en) | 2001-10-18 | 2009-08-18 | Samyang Corporation | Polymeric micelle composition with improved stability |
JP4425536B2 (ja) | 2001-10-30 | 2010-03-03 | 株式会社吉野工業所 | 容器とその熱成形装置および熱成形方法 |
US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
JP2005513057A (ja) | 2001-12-15 | 2005-05-12 | スフェリックス, インコーポレイテッド | 胃保持が増加する生体接着性薬物送達システム |
US20030235619A1 (en) | 2001-12-21 | 2003-12-25 | Christine Allen | Polymer-lipid delivery vehicles |
AU2002357003A1 (en) | 2001-12-28 | 2003-07-24 | Guilford Pharmaceuticals Inc. | Indoles as naaladase inhibitors |
EP1472541B1 (en) | 2002-01-10 | 2009-09-16 | The Johns Hopkins University | Imaging agents and methods of imaging naaladase of psma |
US6720008B2 (en) | 2002-01-22 | 2004-04-13 | Pr Pharmaceuticals, Inc. | Composition and method for the encapsulation of water-soluble molecules into nanoparticles |
US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
CN1305932C (zh) | 2002-02-22 | 2007-03-21 | 植入疗法公司 | 碳水化合物修饰的聚合物、其组合物及其应用 |
US20030232013A1 (en) | 2002-02-22 | 2003-12-18 | Gary Sieckman | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
CA2476657A1 (en) | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Haloacetamide and azide substituted compounds and methods of use thereof |
US7705182B2 (en) | 2002-02-28 | 2010-04-27 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
US7803970B2 (en) | 2002-02-28 | 2010-09-28 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
WO2003074450A2 (en) | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
WO2003086369A2 (en) | 2002-04-05 | 2003-10-23 | Valorisation-Recherche, Societe En Commandite | Stealthy polymeric biodegradable nanospheres and uses thereof |
US7285289B2 (en) | 2002-04-12 | 2007-10-23 | Nagy Jon O | Nanoparticle vaccines |
CN100419426C (zh) | 2002-04-22 | 2008-09-17 | 佛罗里达州立大学 | 功能化纳米微粒及其使用方法 |
JP2003342168A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | 注射用薬物含有ポリマーミセル製剤の製造方法 |
US6819165B2 (en) | 2002-05-30 | 2004-11-16 | Analog Devices, Inc. | Voltage regulator with dynamically boosted bias current |
EP1531800B1 (en) | 2002-06-11 | 2011-06-08 | Ethypharm | Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
US7741371B2 (en) | 2002-06-17 | 2010-06-22 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
TW200407280A (en) | 2002-06-17 | 2004-05-16 | Univ Tennessee Res Foundation | N-bridged selective androgen receptor modulators and methods of use thereof |
US20040092470A1 (en) | 2002-06-18 | 2004-05-13 | Leonard Sherry A. | Dry powder oligonucleotide formualtion, preparation and its uses |
EP1552002A4 (en) | 2002-06-18 | 2006-02-08 | Archemix Corp | APTAMER TOXIN MOLECULES AND METHOD FOR THEIR USE |
US7767803B2 (en) | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
ATE488246T1 (de) | 2002-08-15 | 2010-12-15 | 3M Innovative Properties Co | Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort |
US6875605B1 (en) * | 2002-08-21 | 2005-04-05 | Florida State University Research Foundation, Inc. | Modular cell culture bioreactor and associated methods |
US7488792B2 (en) | 2002-08-28 | 2009-02-10 | Burnham Institute For Medical Research | Collagen-binding molecules that selectively home to tumor vasculature and methods of using same |
AU2003267583A1 (en) | 2002-09-19 | 2004-04-08 | The Chancellor, Master And Scholars Of The University Of Oxford | Molecular arrays and single molecule detection |
US7008411B1 (en) | 2002-09-30 | 2006-03-07 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for treating vulnerable plaque |
CA2502209A1 (en) | 2002-10-15 | 2004-04-29 | University Of Tennessee Research Foundation | Methylene-bridged selective androgen receptor modulators and methods of use thereof |
US20040087810A1 (en) | 2002-10-23 | 2004-05-06 | Dalton James T. | Irreversible selective androgen receptor modulators and methods of use thereof |
JP2006512391A (ja) | 2002-12-30 | 2006-04-13 | スリーエム イノベイティブ プロパティズ カンパニー | 組み合わせ免疫賦活薬 |
PT1592658E (pt) | 2003-01-13 | 2013-06-25 | Univ Tennessee Res Foundation | Síntese em larga escala de modulador selectivo de receptor de androgénio |
US20040156846A1 (en) | 2003-02-06 | 2004-08-12 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles using L6 antibodies |
EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8 |
DE602004008582T2 (de) | 2003-02-17 | 2008-05-21 | Peter Burkhard | Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme |
US20040167103A1 (en) | 2003-02-24 | 2004-08-26 | Dalton James T. | Haloacetamide and azide substituted compounds and methods of use thereof |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
CN1812766A (zh) | 2003-04-25 | 2006-08-02 | 宾州研究基金会 | 用于全身传递使生长停滞的、衍生于脂质的生物活性化合物的方法和系统 |
US20050008572A1 (en) | 2003-04-29 | 2005-01-13 | Ales Prokop | Nanoparticular tumor targeting and therapy |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
WO2004103159A2 (en) | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
GB0312309D0 (en) | 2003-05-29 | 2003-07-02 | Gaslini Children S Hospital G | Targeted liposome |
US20060239907A1 (en) | 2003-06-03 | 2006-10-26 | The Trustees Of The University Of Pennsylvania | Stealthy nano agents |
US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
US7149574B2 (en) | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
EP2356999A1 (en) | 2003-06-17 | 2011-08-17 | Mannkind Corporation | Compositions to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
JP4701169B2 (ja) | 2003-06-30 | 2011-06-15 | カンジ,インコーポレイテッド | アデノウイルスのポリマーカプセル化 |
US20050256071A1 (en) | 2003-07-15 | 2005-11-17 | California Institute Of Technology | Inhibitor nucleic acids |
EP1648519B1 (en) | 2003-07-16 | 2014-10-08 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
US7362068B2 (en) | 2003-07-23 | 2008-04-22 | Asmo Co., Ltd. | Closing member control system |
WO2005022147A1 (en) | 2003-08-28 | 2005-03-10 | Celula, Inc. | Methods and apparatus for sorting cells using an optical switch in a microfluidic channel network |
US20050100877A1 (en) | 2003-09-02 | 2005-05-12 | University Of North Carolina At Chapel Hill | Biodegradable polymer-ligand conjugates and their uses in isolation of cellular subpolulations and in cryopreservation, culture and transplantation of cells |
AU2004281634B2 (en) | 2003-09-03 | 2011-01-27 | Dendritherapeutics, Inc. | Multiplex vaccines |
KR101200729B1 (ko) | 2003-09-17 | 2012-11-13 | 넥타르 테라퓨틱스 | 다분지형 고분자 전구약물 |
CA2558916C (en) | 2003-10-20 | 2009-09-22 | William Marsh Rice University | Method to fabricate microcapsules from polymers and charged nanoparticles |
US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
JP2007510160A (ja) | 2003-10-28 | 2007-04-19 | アリックス インコーポレイテッド | ホログラフィック光トラッピングを用いて物質を操作し、処理するためのシステム及び方法 |
WO2005055949A2 (en) | 2003-12-09 | 2005-06-23 | The Children's Hospital Of Philadelphia | Sustained release preparations composed of biocompatible complex microparticles |
ES2625345T3 (es) | 2003-12-19 | 2017-07-19 | The University Of North Carolina At Chapel Hill | Métodos para fabricar micro- y nanoestructuras usando litografía blanda o de impresión |
US7846412B2 (en) | 2003-12-22 | 2010-12-07 | Emory University | Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof |
US7335744B2 (en) | 2003-12-23 | 2008-02-26 | The Regents Of The California University | Prostate cancer specific internalizing human antibodies |
WO2005065418A2 (en) | 2003-12-31 | 2005-07-21 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy |
EP1713514B1 (en) | 2004-01-28 | 2021-11-24 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
AU2005219443A1 (en) | 2004-03-03 | 2005-09-15 | Spherics, Inc. | Polymeric drug delivery system for hydrophobic drugs |
WO2005110438A2 (en) * | 2004-04-15 | 2005-11-24 | Massachusetts Institute Of Technology | Methods and products related to the intracellular delivery of polysaccharides |
JP4584986B2 (ja) | 2004-04-27 | 2010-11-24 | アルニラム ファーマスーティカルズ インコーポレイテッド | 2−アリールプロピル部分を含む1本鎖及び2本鎖オリゴヌクレオチド |
ES2246695B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico. |
US8821859B2 (en) | 2004-05-19 | 2014-09-02 | Agency For Science, Technology And Research | Methods and articles for the delivery of therapeutic agents |
CN100475837C (zh) | 2004-06-11 | 2009-04-08 | 北京键凯科技有限公司 | 多叉分支的聚乙二醇-氨基酸寡肽及其活性衍生物和药物结合物 |
US20080124400A1 (en) | 2004-06-24 | 2008-05-29 | Angiotech International Ag | Microparticles With High Loadings Of A Bioactive Agent |
JP2008512350A (ja) | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
US20060258628A1 (en) | 2004-07-20 | 2006-11-16 | Steiner Mitchell S | Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof |
CA2573359A1 (en) * | 2004-07-22 | 2006-02-02 | Genentech, Inc. | Method of treating sjogren's syndrome |
KR100604976B1 (ko) | 2004-09-03 | 2006-07-28 | 학교법인연세대학교 | 다작용기 리간드로 안정화된 수용성 나노입자 |
WO2005111192A1 (en) | 2004-09-22 | 2005-11-24 | Catchmabs Bv | Bioreactor assembly comprising at least one tray-like rocking platform |
CA2582668C (en) | 2004-10-01 | 2013-10-01 | Midatech Ltd | Nanoparticles comprising antigens and adjuvants, and immunogenic structures |
EP1812864A2 (en) | 2004-10-07 | 2007-08-01 | Emory University | Multifunctional nanoparticles conjugates and their use |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
US20060111271A1 (en) | 2004-11-24 | 2006-05-25 | Cerny Erich H | Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements |
EP1824872B1 (en) | 2004-12-14 | 2012-02-08 | Alnylam Pharmaceuticals Inc. | Rnai modulation of mll-af4 and uses thereof |
WO2006090924A1 (ja) | 2005-02-28 | 2006-08-31 | The University Of Tokyo | ペプチドリガンドを有するブロック共重合体 |
WO2006093991A1 (en) | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
WO2006096754A2 (en) | 2005-03-07 | 2006-09-14 | Archemix Corp. | Stabilized aptamers to psma and their use as prostate cancer therapeutics |
WO2006099445A2 (en) | 2005-03-14 | 2006-09-21 | Massachusetts Institute Of Technology | Nanocells for diagnosis and treatment of diseases and disorders |
ES2396240T3 (es) | 2005-04-20 | 2013-02-20 | Mitsuru Akashi | Poliaminoácido para usar como adyuvante |
CA2607185A1 (en) | 2005-05-04 | 2006-11-09 | Noxxon Pharma Ag | Intracellular active agents |
US8088908B2 (en) | 2005-05-10 | 2012-01-03 | City Of Hope | Humanized anti-prostate stem cell antigen monoclonal antibody |
WO2006133271A2 (en) | 2005-06-06 | 2006-12-14 | The General Hospital Corporation | Compositions and methods relating to target-specific photodynamic therapy |
WO2006138463A2 (en) | 2005-06-17 | 2006-12-28 | Nektar Therapeutics Al, Corporation | Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs |
TW200800209A (en) | 2005-07-11 | 2008-01-01 | Wyeth Corp | Glutamate aggrecanase inhibitors |
CN101287835A (zh) | 2005-08-17 | 2008-10-15 | 株式会社百奥尼 | 用于siRNA细胞内输送的siRNA-亲水性聚合物结合物及其方法 |
EP1932538A4 (en) | 2005-08-25 | 2009-10-21 | Taiho Pharmaceutical Co Ltd | BIODEGRADABLE NANOTEHICLES WITH IMMOBILIZED OR CAPACITATED T-CELL-RECOGNIZABLE EPITOPEPEPID |
US20080267876A1 (en) | 2005-09-20 | 2008-10-30 | Yissum Research Development Company | Nanoparticles for Targeted Delivery of Active Agent |
JP5484732B2 (ja) | 2005-12-14 | 2014-05-07 | サイトス バイオテクノロジー アーゲー | 過敏症の治療のための免疫賦活性核酸パッケージ粒子 |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
AU2006330610B2 (en) | 2005-12-19 | 2012-08-16 | Pharmain Corporation | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
US20070233534A1 (en) | 2006-01-06 | 2007-10-04 | Marware Inc. | Project management system and method |
US20070231392A1 (en) | 2006-01-23 | 2007-10-04 | Ernst Wagner | CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY |
US8021689B2 (en) | 2006-02-21 | 2011-09-20 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | Nanoparticles for immunotherapy |
WO2007109364A2 (en) | 2006-03-20 | 2007-09-27 | The General Hospital Corporation | Intramolecularly quenched fluorochrome conjugates and methods of use |
US20070225213A1 (en) | 2006-03-23 | 2007-09-27 | Kosak Matthew K | Nucleic acid carriers for delivery of therapeutic agents |
ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
WO2008051291A2 (en) | 2006-04-11 | 2008-05-02 | Ordway Research Institute | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
EP1854478A1 (en) * | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
US20110052697A1 (en) | 2006-05-17 | 2011-03-03 | Gwangju Institute Of Science & Technology | Aptamer-Directed Drug Delivery |
US7674924B2 (en) * | 2006-05-22 | 2010-03-09 | Third Wave Technologies, Inc. | Compositions, probes, and conjugates and uses thereof |
CN101467235A (zh) | 2006-06-13 | 2009-06-24 | Nxp股份有限公司 | 双栅极晶体管及其制造方法 |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US20090117549A1 (en) | 2006-07-18 | 2009-05-07 | Weihong Tan | Aptamer-based methods for identifying cellular biomarkers |
US20100144845A1 (en) | 2006-08-04 | 2010-06-10 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
US20080171059A1 (en) | 2006-08-07 | 2008-07-17 | Shanshan Wu Howland | Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens |
US20080057103A1 (en) | 2006-08-21 | 2008-03-06 | Wouter Roorda | Methods of using medical devices for controlled drug release |
WO2008041703A1 (fr) * | 2006-10-02 | 2008-04-10 | Osaka University | Adjuvant pour vaccin contre la grippe et vaccin contre la grippe |
SI2097111T1 (sl) | 2006-11-08 | 2016-02-29 | Molecular Insight Pharmaceuticals, Inc. | Heterodimeri glutaminske kisline |
US20100303723A1 (en) | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
EP2099496A2 (en) | 2006-12-08 | 2009-09-16 | Massachusetts Institute of Technology | Delivery of nanoparticles and/or agents to cells |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
WO2008124632A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
US20080311045A1 (en) | 2007-06-06 | 2008-12-18 | Biovaluation & Analysis, Inc. | Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo |
HUE035101T2 (hu) | 2007-09-28 | 2018-05-02 | Pfizer | Ráksejtek célzása nanorészecskék alkalmazásával |
AU2008314647B2 (en) | 2007-10-12 | 2013-03-21 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
AU2009221419B2 (en) | 2008-02-01 | 2013-09-26 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles useful as vaccines |
EP2106806A1 (en) | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
EA020753B1 (ru) | 2008-06-16 | 2015-01-30 | Бинд Терапьютикс, Инк. | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение |
PT2774608T (pt) | 2008-06-16 | 2020-01-17 | Pfizer | Nanopartículas poliméricas carregadas com fármaco e métodos de produção e utilização das mesmas |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
WO2010114770A1 (en) | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
WO2010114768A1 (en) | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-epothilone conjugates, particles, compositions, and related methods of use |
US8357401B2 (en) | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
-
2009
- 2009-04-22 US US12/428,388 patent/US8591905B2/en active Active
- 2009-10-09 EP EP09740581.5A patent/EP2346528B1/en active Active
- 2009-10-09 CN CN2009801499156A patent/CN102245200A/zh active Pending
- 2009-10-09 CA CA2740248A patent/CA2740248C/en active Active
- 2009-10-09 KR KR1020117010819A patent/KR20110074903A/ko not_active Application Discontinuation
- 2009-10-09 RU RU2011118880/15A patent/RU2487712C2/ru active
- 2009-10-09 AU AU2009303334A patent/AU2009303334B2/en active Active
- 2009-10-09 JP JP2011531220A patent/JP5854837B2/ja active Active
- 2009-10-09 US US13/123,886 patent/US8932595B2/en active Active
- 2009-10-09 MX MX2011003846A patent/MX336721B/es unknown
- 2009-10-09 WO PCT/US2009/060236 patent/WO2010042866A1/en active Application Filing
- 2009-10-09 BR BRPI0920282A patent/BRPI0920282A2/pt not_active Application Discontinuation
-
2011
- 2011-04-10 IL IL212244A patent/IL212244A/en active IP Right Grant
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5942252A (en) * | 1986-10-24 | 1999-08-24 | Southern Research Institute | Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their release |
US6232082B1 (en) * | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
EA004956B1 (ru) * | 1998-12-01 | 2004-10-28 | эНЭйБиАй БАЙОФАМЭСЬЮТИКЭЛЗ | Конъюгат гаптен-носитель (варианты), антитело и способ его получения, функциональный фрагмент антитела, набор для определения присутствия никотина в образце, вакцинная композиция (варианты) и способ профилактики или лечения никотиновой аддикции (варианты) |
US20080026000A1 (en) * | 1998-12-01 | 2008-01-31 | Nabi Biopharmaceuticals | Hapten-carrier conjugates for treating and preventing nicotine addiction |
CA2453959A1 (en) * | 2001-07-17 | 2003-01-30 | Universidade Federal De Minas Gerais-Ufmg | Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres |
US20040059094A1 (en) * | 2002-07-18 | 2004-03-25 | Bachmann Martin F. | Hapten-carrier conjugates and uses thereof |
WO2005112885A2 (en) * | 2004-05-12 | 2005-12-01 | Baxter International Inc. | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
CA2649149A1 (en) * | 2006-04-11 | 2007-10-25 | Koko Kosmetikvertrieb Gmbh & Co. Kg | Nanoparticle containing nicotine and/or cotinine, dispersions, and use thereof |
Non-Patent Citations (5)
Title |
---|
GORELIK J. et al. Scanning surface confocal microscopy for simultaneous topographical and fluorescence imaging: application to single virus-like particle entry into a cell. Proc. Natl. Acad. Sci. USA 2002 Dec 10; 99(25): 16018-23 [он-лайн] [найдено 2012-08-06] (Найдено из базы данных PubMed PMID: 12466501). * |
GORELIK J. et al. Scanning surface confocal microscopy for simultaneous topographical and fluorescence imaging: application to single virus-like particle entry into a cell. Proc. Natl. Acad. Sci. USA 2002 Dec 10; 99(25): 16018-23 [он-лайн] [найдено 2012-08-06] (Найдено из базы данных PubMed PMID: 12466501). YU D. et al. Engineered bio-nanocapsules, the selective vector for drug delivery system. IUBMB Life 2006 Jan; 58 (1):1-6 Реферат. * |
MANOLOVA V. et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J.Immunol. 2008 May; 38 (5): 1404-13 Реферат [он-лайн]. [найдено 2012-08-06] (Найдено из базы данных PubMed PMID: 18389478). * |
YU D. et al. Engineered bio-nanocapsules, the selective vector for drug delivery system. IUBMB Life 2006 Jan; 58 (1):1-6 Реферат. Никотин, RN:54-11-5 (Nicotine [USAN] [он-лайн] [найдено 2012-08-06] (Найдено из базы данных ChemIDplus). * |
Никотин, RN:54-11-5 (Nicotine [USAN] [он-лайн] [найдено 2012-08-06] (Найдено из базы данных ChemIDplus). * |
Also Published As
Publication number | Publication date |
---|---|
RU2011118880A (ru) | 2012-11-20 |
JP5854837B2 (ja) | 2016-02-09 |
US8591905B2 (en) | 2013-11-26 |
MX2011003846A (es) | 2011-09-27 |
AU2009303334B2 (en) | 2013-07-04 |
CA2740248A1 (en) | 2010-04-15 |
CN102245200A (zh) | 2011-11-16 |
BRPI0920282A2 (pt) | 2016-08-02 |
EP2346528A1 (en) | 2011-07-27 |
US20100092425A1 (en) | 2010-04-15 |
AU2009303334A1 (en) | 2010-04-15 |
JP2012505246A (ja) | 2012-03-01 |
WO2010042866A1 (en) | 2010-04-15 |
IL212244A0 (en) | 2011-06-30 |
CA2740248C (en) | 2014-08-05 |
US20120027808A1 (en) | 2012-02-02 |
US8932595B2 (en) | 2015-01-13 |
IL212244A (en) | 2016-02-29 |
MX336721B (es) | 2016-01-28 |
EP2346528B1 (en) | 2016-04-06 |
KR20110074903A (ko) | 2011-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2487712C2 (ru) | Никотиновые иммунонанотерапевтические лекарственные средства | |
RU2497542C2 (ru) | Нацеливание на антигенпрезентирующие клетки иммунонанотерапевтических средств | |
Hanson et al. | Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants | |
RU2496517C2 (ru) | Включение адъюванта в иммунонанотерапевтические средства | |
Singha et al. | Nanoparticles for immune stimulation against infection, cancer, and autoimmunity | |
Moyer et al. | Beyond antigens and adjuvants: formulating future vaccines | |
JP7491869B2 (ja) | ペプチドコンジュゲート粒子 | |
Rajput et al. | Dendritic cell-targeted nanovaccine delivery system prepared with an immune-active polymer | |
Dong et al. | A visible codelivery nanovaccine of antigen and adjuvant with self-carrier for cancer immunotherapy | |
JP2012505245A5 (ru) | ||
Rudra et al. | Suppression of cocaine-evoked hyperactivity by self-adjuvanting and multivalent peptide nanofiber vaccines | |
De Geest et al. | Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection | |
Wu et al. | Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization | |
JP2012505248A5 (ru) | ||
JP2017079745A (ja) | IL‐15とIL‐15Rαとの複合体及びその使用 | |
JP2012505249A5 (ru) | ||
Barrett et al. | Modular peptide amphiphile micelles improving an antibody-mediated immune response to group A streptococcus | |
CN105814083A (zh) | 嵌合抗原受体t细胞开关和其用途 | |
Das et al. | Biocompatible chitosan nanoparticles as an efficient delivery vehicle for Mycobacterium tuberculosis lipids to induce potent cytokines and antibody response through activation of γδ T cells in mice | |
JP2022101576A (ja) | スギ花粉エピトープを封入するtimp(組織性メタロプロテアーゼ阻害因子) | |
Hanson et al. | Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding | |
CN112933234A (zh) | 非免疫抑制性抗原特异性免疫治疗剂的重复施用 | |
Rajananthanan et al. | Novel aggregate structure adjuvants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice | |
Bakkari et al. | Toll-like receptor-4 (TLR4) agonist-based intranasal nanovaccine delivery system for inducing systemic and mucosal immunity | |
CN106110320A (zh) | 抗原性组合物和方法 |